New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch
New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF) New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF) New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)
Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients
Results from Phase II MASH trial announced at EASL 2024 Results from Phase II MASH trial announced at EASL 2024 Boehringer Ingelheim announced results from Phase II trial in metabolic dysfunction-associated steatohepatitis (MASH) at EASL 2024